The partial efficacy of PARP inhibitors in the small population of BRCA mutant carriers, the resistance of a variety of cancer types to the currently approved PARP inhibitors, their side effects and the unclear impact of their chemical structure on their potency [21,22,23,24,25,26], urged a further investigation of the activity of PARP inhibitors in cancer therapy. Here, PARP1 is linked to cancer.